{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:42Z","timestamp":1792785042633,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["2171\/2595, CIBERINFEC"],"award-info":[{"award-number":["2171\/2595, CIBERINFEC"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD23\/00136, Sara Borrell program"],"award-info":[{"award-number":["CD23\/00136, Sara Borrell program"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016386","name":"Conselleria de Innovaci\u00f3n, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana","doi-asserted-by":"publisher","award":["CIPROM\/2024\/12"],"award-info":[{"award-number":["CIPROM\/2024\/12"]}],"id":[{"id":"10.13039\/501100016386","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Salud Carlos III, Ministerio de Ciencia e Innovaci\u00f3n and Uni\u00f3n Europea \u2013 NextGenerationEU","award":["CIBER -Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red-(CB21\/13\/00011)"],"award-info":[{"award-number":["CIBER -Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red-(CB21\/13\/00011)"]}],"id":[{"id":"https:\/\/ror.org\/05r0vyz12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56663-7","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T19:44:20Z","timestamp":1783280660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiviral therapy and interleukin-6 blockade associated with lower thrombotic risk in hospitalized COVID-19: a target trial emulation"],"prefix":"10.1038","volume":"16","author":[{"given":"Sergio","family":"Padilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Andreo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Telenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bello-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mascarell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Botella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Abell\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Masi\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,5]]},"reference":[{"key":"56663_CR1","doi-asserted-by":"publisher","first-page":"102887","DOI":"10.1016\/j.ebiom.2020.102887","volume":"58","author":"P Domingo","year":"2020","unstructured":"Domingo, P. et al. The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19). EBioMedicine 58, 102887. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102887 (2020).","journal-title":"EBioMedicine"},{"issue":"8","key":"56663_CR2","doi-asserted-by":"publisher","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","volume":"7","author":"G Goshua","year":"2020","unstructured":"Goshua, G. et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol 7(8), e575\u2013e582. https:\/\/doi.org\/10.1016\/S2352-3026(20)30216-7 (2020).","journal-title":"Lancet Haematol"},{"key":"56663_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","volume":"26","author":"A Gupta","year":"2020","unstructured":"Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nature Medicine 26, 1017\u20131032. https:\/\/doi.org\/10.1038\/s41591-020-0968-3 (2020).","journal-title":"Nature Medicine"},{"key":"56663_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok, F. A. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research 191, 145\u2013147. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.013 (2020).","journal-title":"Thrombosis Research"},{"key":"56663_CR5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S1473-3099(22)00223-7","volume":"22","author":"E Burn","year":"2022","unstructured":"Burn, E. et al. Venous or arterial thrombosis and deaths among COVID-19 cases: A European network cohort study. Lancet Infect Dis 22, 1142\u20131152. https:\/\/doi.org\/10.1016\/S1473-3099(22)00223-7 (2022).","journal-title":"Lancet Infect Dis"},{"key":"56663_CR6","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.123.063901","volume":"147","author":"G Piazza","year":"2023","unstructured":"Piazza, G. et al. Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: A randomized clinical trial. Circulation 147, 1891\u20131901. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.063901 (2023).","journal-title":"Circulation"},{"key":"56663_CR7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1001\/jama.2022.2361","volume":"327","author":"JM Connors","year":"2022","unstructured":"Connors, J. M. & Ridker, P. M. Thromboinflammation and antithrombotic therapy in COVID-19. JAMA 327, 1234\u20131235. https:\/\/doi.org\/10.1001\/jama.2022.2361 (2022).","journal-title":"JAMA"},{"key":"56663_CR8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","volume":"181","author":"AC Spyropoulos","year":"2021","unstructured":"Spyropoulos, A. C. et al. Efficacy and safety of therapeutic-dose heparin versus standard prophylactic or intermediate-dose heparins in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern. Med. 181, 1612\u20131620. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6203 (2021).","journal-title":"JAMA Intern. Med."},{"key":"56663_CR9","doi-asserted-by":"publisher","first-page":"CD015102","DOI":"10.1002\/14651858.CD015102.pub2","volume":"8","author":"BC Santos","year":"2023","unstructured":"Santos, B. C., Flumignan, R. L. G., Civile, V. T., Atallah, \u00c1. N. & Nakano, L. C. U. Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database Syst. Rev. 8, CD015102. https:\/\/doi.org\/10.1002\/14651858.CD015102.pub2 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"56663_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 386, 1397\u20131408. https:\/\/doi.org\/10.1056\/NEJMoa2118542 (2022).","journal-title":"N Engl J Med"},{"key":"56663_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"AJ Bernal","year":"2022","unstructured":"Bernal, A. J. et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl. J. Med. 386, 509\u2013520. https:\/\/doi.org\/10.1056\/NEJMoa2116044 (2022).","journal-title":"N Engl. J. Med."},{"issue":"22","key":"56663_CR12","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","volume":"6736","author":"WHO Solidarity Trial Consortium","year":"2022","unstructured":"WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 6736(22), 1941\u20131953. https:\/\/doi.org\/10.1016\/S0140-6736(22)00519-0 (2022).","journal-title":"Lancet"},{"key":"56663_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl. J. Med. 384, 693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436 (2021).","journal-title":"N Engl. J. Med."},{"key":"56663_CR14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0 (2021).","journal-title":"Lancet"},{"key":"56663_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417\u20131418. https:\/\/doi.org\/10.1016\/S0140-6736(20)30937-5 (2020).","journal-title":"Lancet"},{"key":"56663_CR16","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.3390\/jcm10225366","volume":"10","author":"D Sagris","year":"2021","unstructured":"Sagris, D. et al. Immunomodulation and reduction of thromboembolic risk in hospitalized COVID-19 patients: systematic review and meta-analysis. J. Clin. Med. 10, 5366. https:\/\/doi.org\/10.3390\/jcm10225366 (2021).","journal-title":"J. Clin. Med."},{"key":"56663_CR17","doi-asserted-by":"publisher","first-page":"16684","DOI":"10.1038\/s41598-020-74001-3","volume":"10","author":"L Guill\u00e9n","year":"2020","unstructured":"Guill\u00e9n, L. et al. Preemptive interleukin-6 blockade in patients with COVID-19. Sci. Rep. 10, 16684. https:\/\/doi.org\/10.1038\/s41598-020-74001-3 (2020).","journal-title":"Sci. Rep."},{"key":"56663_CR18","doi-asserted-by":"publisher","first-page":"e0319666","DOI":"10.1371\/journal.pone.0319666","volume":"20","author":"S Padilla","year":"2025","unstructured":"Padilla, S. et al. Enhanced prediction of thrombotic events in hospitalized COVID-19 patients with soluble thrombomodulin. PLoS One. 20, e0319666. https:\/\/doi.org\/10.1371\/journal.pone.0319666 (2025).","journal-title":"PLoS One"},{"key":"56663_CR19","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/jac\/dkac144","volume":"77","author":"S Padilla","year":"2022","unstructured":"Padilla, S. et al. Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. J. Antimicrob. Chemother. 77, 2257\u20132264. https:\/\/doi.org\/10.1093\/jac\/dkac144 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"56663_CR20","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2020.1267","volume":"323","author":"MJ Stensrud","year":"2020","unstructured":"Stensrud, M. J. (ed, M. A.) Why test for proportional hazards? JAMA 323 1401\u20131402 https:\/\/doi.org\/10.1001\/jama.2020.1267 (2020).","journal-title":"JAMA"},{"key":"56663_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern. Med. 167, 268\u2013274. https:\/\/doi.org\/10.7326\/M16-2607 (2017).","journal-title":"Ann. Intern. Med."},{"key":"56663_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","volume":"334","author":"AG Cashin","year":"2025","unstructured":"Cashin, A. G. et al. Transparent reporting of observational studies emulating a target trial: the TARGET statement. JAMA 334, 1084\u20131093. https:\/\/doi.org\/10.1001\/jama.2025.13350 (2025).","journal-title":"JAMA"},{"key":"56663_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/10600280221133376","volume":"57","author":"NK Reid","year":"2022","unstructured":"Reid, N. K., Joyner, K. R. & Lewis-Wolfson, T. D. Baricitinib versus tocilizumab for the treatment of moderate to severe COVID-19. Ann. Pharmacother. 57, 769\u2013775. https:\/\/doi.org\/10.1177\/10600280221133376 (2022).","journal-title":"Ann. Pharmacother"},{"key":"56663_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12959-020-00236-9","volume":"18","author":"B Atallah","year":"2020","unstructured":"Atallah, B. et al. Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients. Thromb. J. 18, 22. https:\/\/doi.org\/10.1186\/s12959-020-00236-9 (2020).","journal-title":"Thromb. J."},{"key":"56663_CR25","doi-asserted-by":"publisher","first-page":"e15208","DOI":"10.7759\/cureus.15208","volume":"13","author":"KH Chan","year":"2021","unstructured":"Chan, K. H. et al. Tocilizumab and thromboembolism in COVID-19: a retrospective hospital-based cohort analysis. Cureus 13, e15208. https:\/\/doi.org\/10.7759\/cureus.15208 (2021).","journal-title":"Cureus"},{"key":"56663_CR26","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.1038\/s41598-025-90278-8","volume":"15","author":"CM Oblitas","year":"2025","unstructured":"Oblitas, C. M. et al. Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events. Sci. Rep. 15, 7722. https:\/\/doi.org\/10.1038\/s41598-025-90278-8 (2025).","journal-title":"Sci. Rep."},{"key":"56663_CR27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.cmi.2025.04.027","volume":"31","author":"O Martinuka","year":"2025","unstructured":"Martinuka, O., le Cessie, S. & Wolkewitz, M. Target trial emulation framework: mitigating methodological challenges and application in COVID-19 treatment evaluation studies. Clin. Microbiol. Infect. 31, 1475\u20131483. https:\/\/doi.org\/10.1016\/j.cmi.2025.04.027 (2025).","journal-title":"Clin. Microbiol. Infect."},{"key":"56663_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/14740338.2024.2382227","volume":"23","author":"J Hu","year":"2024","unstructured":"Hu, J., Sun, Y., Zuo, X. & Zou, Y. Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies. Expert Opin. Drug Saf. 23, 1327\u20131339. https:\/\/doi.org\/10.1080\/14740338.2024.2382227 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"56663_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","volume":"173","author":"SA Johannesdottir","year":"2013","unstructured":"Johannesdottir, S. A. et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern. Med. 173, 743\u2013752. https:\/\/doi.org\/10.1001\/jamainternmed.2013.122 (2013).","journal-title":"JAMA Intern. Med."},{"key":"56663_CR30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/jth.13265","volume":"14","author":"CJ Majoor","year":"2016","unstructured":"Majoor, C. J. et al. The influence of corticosteroids on hemostasis in healthy subjects. J. Thromb. Haemost. 14, 716\u2013723. https:\/\/doi.org\/10.1111\/jth.13265 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"56663_CR31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1055\/s-0040-1722270","volume":"47","author":"C Simion","year":"2021","unstructured":"Simion, C. et al. Use of glucocorticoids and risk of venous thromboembolism: a narrative review. Semin Thromb. Hemost. 47, 654\u2013661. https:\/\/doi.org\/10.1055\/s-0040-1722270 (2021).","journal-title":"Semin Thromb. Hemost."},{"key":"56663_CR32","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060\u20132069. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1 (2021).","journal-title":"Lancet"},{"key":"56663_CR33","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1161\/ATVBAHA.125.322533","volume":"45","author":"S Ministrini","year":"2025","unstructured":"Ministrini, S. et al. Direct interleukin-6 inhibition blunts arterial thrombosis by reducing collagen-mediated platelet activation. Arterioscler. Thromb. Vasc Biol. 45, 1432\u20131439. https:\/\/doi.org\/10.1161\/ATVBAHA.125.322533 (2025).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"56663_CR34","doi-asserted-by":"publisher","first-page":"109135","DOI":"10.1016\/j.thromres.2024.109135","volume":"243","author":"LM Almskog","year":"2024","unstructured":"Almskog, L. M. et al. Tocilizumab reduces hypercoagulation in COVID-19. Thromb. Res. 243, 109135. https:\/\/doi.org\/10.1016\/j.thromres.2024.109135 (2024).","journal-title":"Thromb. Res."},{"key":"56663_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/jama.2025.3807","volume":"334","author":"AM Pishko","year":"2025","unstructured":"Pishko, A. M., Li, A. & Cuker, A. Immune thrombotic thrombocytopenic purpura: a review. JAMA 334, 517\u2013529. https:\/\/doi.org\/10.1001\/jama.2025.3807 (2025).","journal-title":"JAMA"},{"key":"56663_CR36","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1016\/j.jtha.2025.07.025","volume":"23","author":"A Chuklin","year":"2025","unstructured":"Chuklin, A., Chiasakul, T. & Uaprasert, N. Anticoagulants and immunosuppressive therapy for thrombosis in Beh\u00e7et\u2019s syndrome: systematic review and meta-analysis. J. Thromb. Haemost. 23, 3578\u20133589. https:\/\/doi.org\/10.1016\/j.jtha.2025.07.025 (2025).","journal-title":"J. Thromb. Haemost"},{"key":"56663_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4331\/wjbc.v14.i4.72","volume":"14","author":"LG Pagliarin","year":"2023","unstructured":"Pagliarin, L. G. et al. In silico evidence of remdesivir action in blood coagulation cascade modulation in COVID-19 treatment. World J. Biol. Chem. 14, 72\u201383. https:\/\/doi.org\/10.4331\/wjbc.v14.i4.72 (2023).","journal-title":"World J. Biol. Chem."},{"key":"56663_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajem.2023.05.007","volume":"70","author":"M Lucijanic","year":"2023","unstructured":"Lucijanic, M. et al. Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events. Am. J. Emerg. Med. 70, 41\u201345. https:\/\/doi.org\/10.1016\/j.ajem.2023.05.007 (2023).","journal-title":"Am. J. Emerg. Med."},{"key":"56663_CR39","doi-asserted-by":"publisher","first-page":"e074572","DOI":"10.1136\/bmj-2022-074572","volume":"381","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Molnupiravir and risk of post-acute sequelae of COVID-19: cohort study. BMJ 381, e074572. https:\/\/doi.org\/10.1136\/bmj-2022-074572 (2023).","journal-title":"BMJ"},{"key":"56663_CR40","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1182\/bloodadvances.2024014219","volume":"25","author":"DM Siegal","year":"2025","unstructured":"Siegal, D. M. et al. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Adv. 25, 1247\u20131260. https:\/\/doi.org\/10.1182\/bloodadvances.2024014219 (2025).","journal-title":"Blood Adv."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56663-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56663-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56663-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:02:24Z","timestamp":1791205344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56663-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56663"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56663-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,5]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30825"}}